This forum is, obviously, primarily for thyroid issues. But, as most know, the parathyroid glands are physically adjacent to thyroid tissue. And it is well-known that some thyroid treatments (thyroidectomy and radio-active iodine for two) can result in damage to the parathyroids.
We usually have four parathyroid glands but most claim that we can function adequately with just one functioning gland.
Hence, though we might have many members who have had some parathyroid damage, diagnosed hypoparathyroidism is relatively rarely mentioned.
I suspect that this news (albeit many months after the announcements of approval) kight have passed by many members.
Review Article
Published: 04 February 2025
Hypoparathyroidism: diagnosis, management and emerging therapies
Sarah Khan & Aliya A. Khan
Nature Reviews Endocrinology (2025)
Abstract
Hypoparathyroidism is characterized by inadequate parathyroid hormone (PTH) secretion or action and results in hypocalcaemia, and can lead to hyperphosphataemia and hypercalciuria. Most cases of hypoparathyroidism occur as a complication of surgery, with the remainder due to causes including autoimmune disease, genetic causes, infiltrative diseases, mineral deposition or due to abnormalities in serum levels of magnesium. Hypoparathyroidism can cause multisystem disease, with long-term complications resulting from ectopic calcification as well as renal complications with nephrocalcinosis, nephrolithiasis and renal impairment in addition to respiratory, cardiac or neurological manifestations. Conventional therapy consists of oral calcium salts and active vitamin D but it has limitations, including fluctuations in serum levels of calcium and a high pill burden, and can increase the risk of long-term complications. By contrast, PTH replacement therapy can effectively achieve normal serum levels of calcium, and lower serum levels of phosphate. The long-acting PTH analogue, palopegteriparatide, has been shown to normalize urine levels of calcium. In addition, PTH replacement therapy reduces the pill burden. Palopegteriparatide is also associated with improved quality of life in comparison to conventional therapy. This Review summarizes current recommendations regarding the pathophysiology, evaluation and management of hypoparathyroidism and also references the 2022 international hypoparathyroidism guidelines. Palopegteriparatide has now been approved as PTH replacement therapy for hypoparathyroidism. Emerging therapies will also be presented in this Review.
Key points
● Hypoparathyroidism is a complex disease characterized by inadequate secretion or action of parathyroid hormone (PTH), which leads to hypocalcaemia and can lead to hyperphosphataemia and hypercalciuria.
● Hypoparathyroidism is a biochemical diagnosis based on the confirmation of hypocalcaemia in association with a low or inappropriately normal PTH level.
● The aetiology of hypoparathyroidism can be divided into surgical causes (75–80% of cases) and non-surgical causes (20–25% of cases).
● Hypoparathyroidism affects multiple organ systems, including the renal, skeletal, cardiovascular, ophthalmological and neurological systems.
● Conventional treatment of hypoparathyroidism with oral calcium salts and active vitamin D can cause fluctuating serum levels of calcium and can exacerbate hyperphosphataemia and hypercalciuria. Conventional therapy has not consistently been shown to improve quality of life.
● PTH replacement therapy is now possible with palopegteriparatide, which provides a valuable management option for addressing symptomatic hypocalcaemia and might also reduce the long-term complications of hypoparathyroidism.
nature.com/articles/s41574-...
A Wiki link to Palopegteriparatide:
Palopegteriparatide was approved for medical use in the European Union in November 2023, and in the United States in August 2024.
en.wikipedia.org/wiki/Palop...
MHRA Approves YORVIPATH® (palopegteriparatide) in UK for the Treatment of Adults with Chronic Hypoparathyroidism
parathyroiduk.org/news/mhra...
NICE guideline (in development)
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development [GID-TA11454] Expected publication date: 16 July 2025